Gabapentin Should Be Discontinued for Anxiety in This Clinical Context
Gabapentin is not an evidence-based treatment for anxiety disorders and should be tapered off, as you are already receiving appropriate anxiolytic therapy with Lybalvi (which contains olanzapine/samidorphan) and divalproex, both of which have demonstrated efficacy for anxiety symptoms in bipolar disorder. 1
Why Discontinue Gabapentin
Gabapentin lacks robust evidence for anxiety disorders. The 2023 World Federation of Societies of Biological Psychiatry guidelines for anxiety disorders do not recommend gabapentin as a treatment option, with SSRIs, SNRIs, and cognitive behavioral therapy being first-line interventions 2
Your current medications already address anxiety. Divalproex has demonstrated benefit for nonspecific anxiety in bipolar disorder and may be the mood stabilizer of choice for anxious patients with bipolar disorder 1. Olanzapine (contained in Lybalvi) has shown superiority over lamotrigine for anxiety when used to augment lithium treatment in bipolar patients 1
Gabapentin evidence is limited to neuropathic pain. The available guidelines focus on gabapentin's use for neuropathic pain conditions (postherpetic neuralgia, diabetic peripheral neuropathy), not anxiety disorders 3
Observational data only suggests "potential efficacy." The only mention of gabapentin for anxiety in bipolar disorder comes from weak observational studies, not controlled trials 1
Tapering Strategy
Given the dose of 309 mg three times daily (927 mg total daily), a gradual taper over 2-3 months is recommended to avoid withdrawal symptoms.
Withdrawal Risk Considerations
Gabapentin can cause severe withdrawal even with tapering. Case reports document debilitating withdrawal symptoms occurring after gradual week-long tapers, with recommendations that gabapentin tapers should follow a benzodiazepine-like approach—slowly over weeks to months 4
Withdrawal symptoms can include: mental status changes, severe somatic complaints, hypertension, anxiety rebound, and flu-like symptoms 4. In severe dependence cases, withdrawal symptoms have required tapers lasting up to 18 months 5
Recommended Taper Schedule
Month 1:
- Reduce by 100 mg daily (approximately 33 mg per dose)
- New dose: approximately 275 mg three times daily 5
Month 2:
- Reduce by another 100 mg daily
- New dose: approximately 242 mg three times daily 5
Month 3:
- Reduce by 100 mg daily
- New dose: approximately 209 mg three times daily 5
Months 4-5:
- Once below 300 mg total daily, slow the taper to 20-30 mg decrements per month 5
- Monitor closely for withdrawal symptoms
Final phase:
- For the last 100 mg, consider 5 mg decrements every 1-2 weeks if withdrawal symptoms emerge 5
Important Caveats
Do not abruptly discontinue. The FDA label specifies that gabapentin should be reduced, discontinued, or substituted gradually over a minimum of 1 week, though a longer period may be needed 6
Monitor for withdrawal symptoms including anxiety rebound, agitation, insomnia, tremor, sweating, and flu-like symptoms 4. If severe symptoms develop, slow or pause the taper 5
Renal function matters. If you have any degree of renal impairment, gabapentin clearance is reduced and withdrawal risk may be higher 3, 6
The taper can be accelerated if you tolerate dose reductions well without withdrawal symptoms. Conversely, if withdrawal symptoms emerge, the taper should be slowed significantly 5, 4
Drug Interaction Considerations
Gabapentin has few drug interactions with your current regimen (Lybalvi, divalproex, trazodone) 3
Lybalvi contains samidorphan, an opioid antagonist. Ensure you are not taking any opioid medications, as this is contraindicated 7
Sedation may decrease as gabapentin is tapered, since both gabapentin and your other medications (olanzapine, trazodone) can cause dose-dependent sedation 3